Michael Pfreundschuh

Author

Also Known As

Andreas Neubauer, C. Zwick, Frank Stegelmann, Henning Madry, M G Pfreundschuh, M PFREUNDSCHUH, M Pfreundschuh, M. PFREUNDSCHUH, M. Pfreundschuh, M. Ziepert

740

Publications

44.8K

Citations

H-Index

179

Concepts

All Affiliations

Saarland University Leipzig University Universitätsklinikum des Saarlandes Heidelberg University University of Göttingen

About

Michael Pfreundschuh is an author at Saarland University specializing in medicine, pathology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	58	147	18.6K
2	Health Sciences	21	25	3K
3	Natural Sciences	5	5	288
4	Engineering	1	1	135
5	Public Health	1	1	14

Michael Pfreundschuh

322

Publications

41.1K

Citations

H-Index

Page 1

	Year	Citations
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group Michael Pfreundschuh, Lorenz Trümper, Anders Österborg, The Lancet Oncology Hematological MalignancyLymphoid NeoplasiaMabthera International TrialMedicinePathology	2006	2.1K
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes Bjoern Chapuy, Chip Stewart, Andrew Dunford, Nature Medicine Hematological MalignancyLymphoid NeoplasiaMolecular SubtypesImmunologyPathology	2018	1.9K
A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening Yao‐Tseng Chen, Matthew J. Scanlan, Uğur Şahin, Proceedings of the National Academy of Sciences	1997	1.2K
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60) Michael Pfreundschuh, Jöerg Schubert, Marita Ziepert, The Lancet Oncology Hematological MalignancyLymphoid NeoplasiaElderly PatientsMedicineBi-weekly Chop-14	2008	1.1K
Human neoplasms elicit multiple specific immune responses in the autologous host. Uğur Şahin, Ö. Türeci, Holger Schmitt, Proceedings of the National Academy of Sciences ImmunologyPathologyEscherichia ColiAntigen ProcessingImmune System	1995	1.1K
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma Eva Hoster, Martin Dreyling, Wolfram Klapper, Blood	2007	944
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hervé Tilly, María Gomes da Silva, Umberto Vitolo, Annals of Oncology Hematological MalignancyLymphoid NeoplasiaMedicineSurgical PathologyHematology	2015	900
Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease Volker Diehl, Jeremy Franklin, Michael Pfreundschuh, New England Journal of Medicine	2003	827
Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial Pieter Sonneveld, Ingo Schmidt‐Wolf, Bronno van der Holt, Journal of Clinical Oncology	2012	819
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group Michael Pfreundschuh, Evelyn Kuhnt, Lorenz Trümper, The Lancet Oncology Hematological MalignancyLymphoid Neoplasia6-Year ResultsMabthera International TrialMedicine	2011	796

Page 1